2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1776 Regular aspirin use prior to follicular lymphoma diagnosis and event-free survival: Discovery and validation

George A Cholack, MD, MSc, Prokop Vodicka, MD, PhD2, Janek S. Walker, PhD3, Jose C Villasboas, MD4, Thomas M. Habermann, MD5, Michal Masar, MD6, Andrew L. Feldman, MD7, Raphael Mwangi, MS8, Bri Negaard9, Joseph Peter Novak, MS10, Dennis P. Robinson11, Thomas Witzig, MD12, Stephen Maxted Ansell, MD, PhD13, Brad S. Kahl, MD14, Jia Ruan, MD, PhD15, Jonathon B. Cohen, MD, MS16, Chijioke C Nze, MD, MPH17, Susan L. Slager, PhD18, Eric Mou, MD19, Matthew E. Maurer, ScD20, Anne J. Novak, PhD21, Christopher R. Flowers Jr, MD, MS22, Yucai Wang, MD, PhD23, Izidore S. Lossos, M.D.24, Jonathan W. Friedberg, MD25, James R. Cerhan, MD, PhD26
1 Mayo Clinic, Rochester, Minnesota, United States
2 Charles University and General Hospital, Prague, Czech Republic
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Charles University and General Hospital, Prague, Czech Republic
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Washington University School of Medicine, St. Louis, Missouri, United States
15 Weill Cornell Medicine and New York–Presbyterian Hospital, New York, New York, United States
16 Emory University, Atlanta, Georgia, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
19 University of Iowa, Iowa City, Iowa, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 University of Miami, Miami, Florida, United States
25 University of Rochester, Rochester, New York, United States
26 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States

Introduction: Inflammation is a risk factor for follicular lymphoma (FL), and thus could influence tumor development through the phases of elimination, equilibrium, and escape (the immunoediting hypothesis) and impact the tumor microenvironment (TME). We previously reported that regular aspirin use prior to FL diagnosis was associated with superior event-free survival (EFS) (Cholack et al., Hematol. Oncol, 2025). Based on this framework, we aimed to externally validate our previous findings.

Methods: We analyzed newly diagnosed patients with FL grade I-IIIA from the Molecular Epidemiology Resource (MER; enrolled 2002-2015) and Lymphoma Epidemiology of Outcomes (LEO; enrolled 2015-2020) prospective cohorts for discovery and validation, respectively. Self-reported regular aspirin use prior to FL diagnosis was defined as ≥4 times per month for ≥1 year, with all others defined as non-regular users (Liebow et al., Int. J. Cancer, 2021). Co-primary endpoints were EFS (time from diagnosis to disease relapse, retreatment, transformation, or all-cause death) and failure to achieve 24 months of EFS (EFS24; a marker of early management failure and inferior OS if not achieved). We used multivariable Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations of regular aspirin use with EFS. We used logistic regression to estimate odds ratios (ORs) and 95% CIs for the association with failure to achieve EFS24. All models were adjusted for age at diagnosis, sex, follicular lymphoma international prognostic index (FLIPI), body mass index (BMI), number of comorbidities, and front-line (1L) management (observation, immunochemotherapy [IC], or other), and in ad-hoc analyses stratified by 1L treatment. In secondary analysis of the pooled cohort, we performed Fine-Gray competing-risks regression treating non-lymphoma death as a competing event to evaluate whether aspirin use was associated with EFS after accounting for competing non-lymphoma mortality.

Results: In the MER cohort (n=521), the median age was 61 years, 51% were male, and 192 (37%) reported regular aspirin use. After a median follow-up of 13.9 years, 317 (61%) had an event, and 139 (27%) died. Aspirin use was associated with superior EFS (HR=0.74, 95% CI: 0.58-0.95) and suggestively better EFS24 rate (OR=0.74, 95% CI: 0.47-1.14). In the LEO validation cohort (n=547), the median age was 60 years, 49% were male, and 239 (44%) reported regular aspirin use. After a median follow-up of 6.8 years, 230 (42%) had an event, and 68 (12%) died. Replicating the MER results, aspirin use was associated with superior EFS (HR=0.68, 95% CI: 0.49-0.93) and better EFS24 rate (OR=0.62, 95% CI: 0.37-1.01). For patients initially managed with observation (n= 190 in MER, n=171 in LEO), aspirin use was associated with superior EFS (HR=0.62, 95% CI: 0.42-0.92) and better EFS24 rate (OR=0.44, 95% CI: 0.21-0.90); these associations were replicated, but attenuated and were not statistically significant in the LEO validation cohort for EFS (HR=0.83, 95% CI 0.46–1.48) and EFS24 failure (OR=0.54, 95% CI: 0.21–1.34). For IC-treated patients (n= 207 in MER, n=219 in LEO), similar effect sizes with aspirin use were observed in the MER (EFS HR=0.69, 95% CI: 0.44–1.08; EFS24 failure OR=0.64, 95% CI: 0.29–1.35) and LEO validation (EFS HR=0.66, 95% CI: 0.39–1.14; EFS24 failure OR=0.65, 95% CI: 0.27–1.52), albeit none of these estimates were statistically significant. When modeling non-lymphoma death as a competing risk, aspirin use remained associated with a lower subdistribution hazard of lymphoma-related events of progression/relapse, transformation or death due to lymphoma (HR=0.70, 95% CI: 0.57-0.86) and 5-year cumulative incidence of lymphoma-related events was lower in aspirin users (35.4%) vs. non-regular users (41.4%).

Conclusions: Regular aspirin use prior to FL diagnosis was associated with better EFS and lower EFS24 failure in the discovery and validation cohorts, with directionally consistent associations across the specified 1L management strategies. Beyond additional replication, these results strengthen the rationale for future studies investigating potential underlying mechanisms of how aspirin use may influence the TME in FL.

George A Cholack, MD, MSc: No relevant conflicts of interest to declare.